BRAF mutation detection in cytological samples from thyroid nodules increases the sensitivity of cytology for the diagnosis of thyroid cancer and is believed to be a marker of aggressive disease. Lee et al. demonstrate high-sensitivity detection of the BRAF mutation with a new assay technique, but disprove the association with tumour aggressiveness.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Xing, M. BRAF mutation in thyroid cancer. Endocr. Relat. Cancer 12, 245–262 (2005).
Lee, S.-T. et al. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. J. Clin. Endocrinol. Metab. http://dx.doi.org/10.1210/jc.2011-3135.
Nikiforov, Y. E. et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J. Clin. Endocrinol. Metab. 94, 2092–2098 (2009).
Cantara, S. et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J. Clin. Endocrinol. Metab. 95, 1365–1369 (2010).
Basolo, F. et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1,060 cases. J. Clin. Endocrinol. Metab. 95, 4197–4205 (2010).
Xing, M. et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J. Clin. Oncol. 27, 2977–2982 (2009).
Pelttari, H. et al. BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. APMIS 120, 380–386 (2012).
Cooper, D. S. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009).
Yip, L. et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J. Clin. Endocrinol. Metab. http://dx.doi.org/10.1210/jc.2011-3048.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Pacini, F. Optimizing molecular testing in thyroid nodule cytology. Nat Rev Endocrinol 8, 390–391 (2012). https://doi.org/10.1038/nrendo.2012.85
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2012.85
